On Friday, Shares of Sirius XM Holdings Inc. (NASDAQ:SIRI), lost -0.51% to $3.88.
Sirius XM Holdings, declared live coverage of the FIFA Women’s World Cup Canada 2015™, starting June 6 on SiriusXM’s Canada Talks (channel 167) for all SiriusXM subscribers.
Being held across Canada , the tournament will run from June 6 to July 5 in Vancouver , Edmonton , Winnipeg , Ottawa , Montreal and Moncton . SiriusXM subscribers will have access to all of Canada’s group stage matches, plus the quarter-finals, semi-finals, final match and more, with all games called by TSN Radio commentator Dan Dunleavy and former member of the Canadian women’s soccer team, Andrea Neil . Listeners will also get TSN Radio’s pre- and post-match shows with host Gareth Wheeler .
Sirius XM Holdings Inc., through its auxiliaries, provides satellite radio services in the United States. The company broadcasts music plus sports, entertainment, comedy, talk, news, traffic, and weather programs, counting various music genres ranging from rock, pop and hip-hop to country, dance, jazz, Latin, and classical; live play-by-play sports from principal leagues and colleges; multitude of talk and entertainment channels for various audiences; national, international, and financial news; and local traffic reports for 22 metropolitan markets.
Shares of eBay Inc. (NASDAQ:EBAY), inclined 1.18% to $63.23, during its last trading session, hitting its highest level.
Terapeak, a leading source for analyzing, understanding and predicting consumer and product behavior in ecommerce, recently declared a major upgrade to its free eBay Listing Analytics tool that now gives sellers a top-down view of their sales performance from a single dashboard housed in eBay’s 3rd party Applications tab. Since introducing Listing Analytics four years ago, it has become the #1 free app in the eBay app store with more than 2.5 million users. Its new dashboard for eBay sellers, also built and powered by Terapeak, provides immediate insights into a seller’s listing performance over specified time periods. Sellers can analyze web traffic and sales performance by category, marketplace and revenue, in addition to isolate individual listings, allowing them to identify the best opportunities to grow their sales.
Listing Analytics users can now visually track their traffic and sales trends with a graphical overview of total impressions, clicks, sales and daily selling price for all eBay marketplaces in which they take part. The dashboard also displays the enhance or decrease in sales and revenue over selected time periods, the percentage of impressions that led to clicks, and the percentage of clicks that converted to sales.
From this summary view, sellers can drill down using any variable or date range to explore the underlying details, compare listings or sales results over time, and identify the causes of performance changes in any area. Individual listings in each category can be sorted by factors ranging from the number of impressions, clicks or sales to price and other listing attributes to facilitate analysis.
eBay Inc. operates as a technology company that enables commerce and payments on behalf of users, merchants, retailers, and brands of various sizes in the United States and internationally. It operates in three segments: Marketplaces, Payments, and Enterprise.
At the end of Friday’s trade, Shares of Noble Corporation plc (NYSE:NE), gained 1.30% to $17.08, as oil prices surged in the final minutes of trade Friday to end higher, having traded down most of the day after OPEC said it would keep output unchanged.
After falling more than $3.00 the past two sessions, US benchmark West Texas Intermediate for July delivery added $1.13 to end at $59.13 a barrel.
In London, Brent crude for July gained $1.28 to $63.31 a barrel, likewise following two days of losses of more than $3.40 a barrel.
Noble Corporation plc operates as an offshore drilling contractor for the oil and gas industry worldwide. It owns and operates a fleet of mobile offshore drilling units. As of December 31, 2014, the company operated a fleet of 15 jackups, 9 drillships, and 8 semisubmersibles, counting 1 high-specification, harsh environment jackup under construction.
Finally, Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL), ended its last trade with 2.79% surge, and closed at $3.68.
Rigel Pharmaceuticals, stated financial results for the first quarter ended March 31, 2015.
For the first quarter of 2015, Rigel stated a net loss of $18.2 million, or $0.21 per share, contrast to a net loss of $22.3 million, or $0.25 per share, in the first quarter of 2014. Weighted average shares outstanding for the first quarters of 2015 and 2014 were 88.0 million and 87.5 million, respectively.
Contract revenues from collaborations of $2.2 million in the first quarter of 2015 were comprised of $2.1 million from the amortization of the $30.0 million upfront payment from Bristol-Myers Squibb (BMS) following the partnership and license agreement executed in February 2015 for the discovery, development and commercialization of potential immuno-oncology therapeutics and $106,000 for Rigel’s performance of research activities in connection with the partnership agreement with BMS. There were no contract revenues from collaborations during the three months ended March 31, 2014.
Rigel stated total operating expenses of $20.4 million in the first quarter of 2015, contrast to $22.4 million in the first quarter of 2014. The decrease in operating expenses was primarily due to the decrease in facilities costs resulting from the effects of the sublease agreement executed in December 2014, in addition to a reduction in research and development costs related to the completion in 2014 of a Phase 2 study of R348 in dry eye and the discontinuation of R118, Rigel’s indirect AMPK activator program. This was partially offset by an enhance in research and development costs related to Rigel’s clinical research programs with fostamatinib in immune thrombocytopenic purpura (ITP) and IgA nephropathy (IgAN).
Rigel Pharmaceuticals, Inc., a clinical-stage drug development company, engages in the discovery and development of small-molecule drugs for the treatment of inflammatory and autoimmune diseases, immuno-oncology related diseases, and muscle disorders.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
